Nammi Therapeutics Completes Series B Round with Investment from MMRF's Myeloma Investment Fund

Nammi Therapeutics announces a $1M investment commitment by the Myeloma Investment Fund in a $30M Series B financing round prior to the planned start of a first-in-human Phase 1 study of our lead program, QXL138AM.

Nammi Therapeutics, Inc. Completes Series B Round with Investment from MMRF's Myeloma Investment Fund; Advances Clinical Development of Lead Program, QXL138AM